Group 1 - Cardiff Oncology reported a quarterly loss of $0.20 per share, slightly worse than the Zacks Consensus Estimate of a loss of $0.19, but an improvement from a loss of $0.22 per share a year ago, indicating a -5.26% earnings surprise [1] - The company posted revenues of $0.11 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 33.94%, and down from $0.21 million in the same quarter last year [2] - Cardiff Oncology shares have declined approximately 42.6% since the beginning of the year, contrasting with the S&P 500's decline of -4.3% [3] Group 2 - The earnings outlook for Cardiff Oncology is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The trend for estimate revisions for Cardiff Oncology is currently favorable, leading to a Zacks Rank 2 (Buy) for the stock, suggesting it is expected to outperform the market in the near future [6] - The current consensus EPS estimate for the upcoming quarter is -$0.19 on revenues of $0.17 million, and for the current fiscal year, it is -$0.78 on revenues of $0.65 million [7] Group 3 - The Medical - Biomedical and Genetics industry, to which Cardiff Oncology belongs, is currently ranked in the top 33% of over 250 Zacks industries, indicating a favorable outlook for stocks in this sector [8] - Another company in the same industry, Immatics, is expected to report a quarterly loss of $0.39 per share, reflecting a significant year-over-year decline of -875%, with revenues projected to be $14.9 million, down 54.7% from the previous year [9]
Cardiff Oncology (CRDF) Reports Q1 Loss, Lags Revenue Estimates